Intech Investment Management LLC Invests $105,000 in Cryoport, Inc. (NASDAQ:CYRX)

Intech Investment Management LLC purchased a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 12,912 shares of the company’s stock, valued at approximately $105,000.

A number of other institutional investors and hedge funds have also made changes to their positions in CYRX. Price T Rowe Associates Inc. MD raised its holdings in shares of Cryoport by 3.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 48,522 shares of the company’s stock worth $859,000 after acquiring an additional 1,438 shares during the last quarter. Comerica Bank raised its holdings in shares of Cryoport by 73.0% in the first quarter. Comerica Bank now owns 3,481 shares of the company’s stock worth $62,000 after acquiring an additional 1,469 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Cryoport by 9.5% in the second quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock worth $122,000 after acquiring an additional 1,534 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Cryoport by 3.4% in the second quarter. Rhumbline Advisers now owns 64,158 shares of the company’s stock worth $443,000 after acquiring an additional 2,086 shares during the last quarter. Finally, Quest Partners LLC raised its holdings in shares of Cryoport by 1,083,000.0% in the second quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock worth $75,000 after acquiring an additional 10,830 shares during the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the sale, the director now owns 59,497 shares of the company’s stock, valued at approximately $443,847.62. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $6.51, for a total value of $325,500.00. Following the sale, the chief executive officer now directly owns 731,897 shares of the company’s stock, valued at approximately $4,764,649.47. This trade represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 109,869 shares of company stock valued at $735,673 over the last quarter. Company insiders own 10.10% of the company’s stock.

Cryoport Price Performance

Shares of NASDAQ:CYRX opened at $7.33 on Friday. The company has a market cap of $362.32 million, a P/E ratio of -2.17 and a beta of 1.62. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a 52 week low of $5.32 and a 52 week high of $20.10. The business has a fifty day simple moving average of $7.31 and a 200-day simple moving average of $8.20.

Wall Street Analysts Forecast Growth

CYRX has been the subject of a number of analyst reports. UBS Group boosted their price target on Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Roth Mkm cut their price target on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.50.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.